The US Food and Drug Administration (FDA) has approved Roxybond (oxycodone hydrochloride) 10mg for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. The approval makes Roxybond the first FDA-approved abuse-deterrent immediate release (IR) 10mg oxycodone formulation that is expected to reduce abuse by intranasal and […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!